Replies to post #297062 on Amarin Corp Plc (AMRN)

[Cardiologymd]

I feel this is our best chance.

Marine population prevalence is 1.1 percent. The article is from the UPTODATE. 1.1 percent. That’s it.

They cannot take 50 percent market and say they are not infringing.

We still have REDUCE IT patent intact.

https://www.fr.com/files/uploads/attachments/Skinny_Labeling_Inducement_of_Patent_Infringement_Nov-Dec-2010.pdf

[sts66]

Does it strike anyone else that these ideas about proving generics are infringing on R-IT patents are just another attempt to justify holding or buying more AMRN? Every time something terrible happens to the stock people look for silver linings - in this case we may be just fooling ourselves into thinking that a silver lining exists. And even if this eventually becomes an actual provable case of infringement, it's probably going to take at least a couple years for proof that generics are infringing R-IT patents, they're not going to go from selling zero to a million scrips in a matter of months, will be supply constricted at first. And I still ask how you prove generics are infringing when insurance is what's driving the substitution.